ERBB2 and breast carcinoma: In order to estimate the cardiac tolerability of trastuzumab after high-dose chemotherapy, we have retrospective analysed the clinical files of HER-2-positive breast cancer patients treated with high-dose chemotherapy in the Italian Centers of the GITMO group (Gruppo Italiano Trapianto Midollo Osseo).